Seeking Alpha

Merck allergy tablet bests placebo in study

  • Merck (MRK) says MK-7243, its sublingual allergy immunotherapy tablet, performed better than placebo over the course of the grass pollen season.
  • "Patients exhibited significant improvement in common allergy symptoms," a study investigator says.
  • Results on TCS (the sum of of the rhinoconjunctivitis daily symptom score and the daily medication score averaged): MK-7243 group demonstrated a 23% improvement versus placebo (P< .001).
  • The FDA is reviewing MRK's BLA for the tablets. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: